Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[THE INVESTOR] Daewha Pharmaceutical said on Oct. 20 that it has terminated its contract with Taiwan’s LOTUS Pharmaceutical to export their co-developed topical anesthetic topical lidocaine patch 5%.
The South Korean drug maker blamed LOTUS for the fallout of the 42.3 billion won deal, saying the Taiwanese partner failed to receive regulatory approvals in China, Europe and the US for the local anesthetic patch, which was one of the preconditions of the contract.
Daehwa said it will receive US$308,196 from LOTUS as compensation.
By Park Han-na (hnpark@heraldcorp.com)
The South Korean drug maker blamed LOTUS for the fallout of the 42.3 billion won deal, saying the Taiwanese partner failed to receive regulatory approvals in China, Europe and the US for the local anesthetic patch, which was one of the preconditions of the contract.
Daehwa said it will receive US$308,196 from LOTUS as compensation.
By Park Han-na (hnpark@heraldcorp.com)
